In the past week, HBIO stock has gone down by -11.77%, with a monthly decline of -49.76% and a quarterly plunge of -68.65%. The volatility ratio for the week is 5.79%, and the volatility levels for the last 30 days are 8.57% for Harvard Bioscience Inc The simple moving average for the last 20 days is -26.83% for HBIO stock, with a simple moving average of -70.40% for the last 200 days.
Is It Worth Investing in Harvard Bioscience Inc (NASDAQ: HBIO) Right Now?
Moreover, the 36-month beta value for HBIO is 1.35. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for HBIO is 37.64M and currently, short sellers hold a 2.56% of that float. On March 12, 2025, HBIO’s average trading volume was 259.94K shares.
HBIO) stock’s latest price update
Harvard Bioscience Inc (NASDAQ: HBIO) has seen a decline in its stock price by -7.03 in relation to its previous close of 0.76. However, the company has experienced a -11.77% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2025-03-12 that Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q4 2024 Results Conference Call March 12, 2025 8:00 AM ET Company Participants Kathryn Flynn – Corporate Controller Jim Green – Chairman, President & CEO Jennifer Cote – CFO & Treasurer Conference Call Participants Paul Knight – KeyBanc Bruce Jackson – The Benchmark Company Operator Good day, and welcome to the Fourth Quarter 2024 Harvard Bioscience Earnings Conference Call. At this time, all participants are in listen-only mode.
Analysts’ Opinion of HBIO
Many brokerage firms have already submitted their reports for HBIO stocks, with The Benchmark Company repeating the rating for HBIO by listing it as a “Buy.” The predicted price for HBIO in the upcoming period, according to The Benchmark Company is $4 based on the research report published on March 10, 2023 of the previous year 2023.
Northland Capital gave a rating of “Outperform” to HBIO, setting the target price at $6 in the report published on December 09th of the previous year.
HBIO Trading at -52.60% from the 50-Day Moving Average
After a stumble in the market that brought HBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.93% of loss for the given period.
Volatility was left at 8.57%, however, over the last 30 days, the volatility rate increased by 5.79%, as shares sank -47.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -66.78% lower at present.
During the last 5 trading sessions, HBIO fell by -13.11%, which changed the moving average for the period of 200-days by -78.86% in comparison to the 20-day moving average, which settled at $0.9676. In addition, Harvard Bioscience Inc saw -66.43% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HBIO starting from Green James W, who purchase 10,000 shares at the price of $2.91 back on Jun 13 ’24. After this action, Green James W now owns 3,111,091 shares of Harvard Bioscience Inc, valued at $29,100 using the latest closing price.
Green James W, the Chief Executive Officer of Harvard Bioscience Inc, purchase 20,000 shares at $3.07 during a trade that took place back on Jun 06 ’24, which means that Green James W is holding 3,101,091 shares at $61,400 based on the most recent closing price.
Stock Fundamentals for HBIO
Current profitability levels for the company are sitting at:
- -0.05 for the present operating margin
- 0.55 for the gross margin
The net margin for Harvard Bioscience Inc stands at -0.13. The total capital return value is set at -0.07. Equity return is now at value -20.40, with -10.51 for asset returns.
Currently, EBITDA for the company is -6.21 million with net debt to EBITDA at 0.84. When we switch over and look at the enterprise to sales, we see a ratio of 0.28. The receivables turnover for the company is 6.33for trailing twelve months and the total asset turnover is 0.74. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.06.
Conclusion
To wrap up, the performance of Harvard Bioscience Inc (HBIO) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
